Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
1 May 2024
| 03:21 | Proteinuria diffhist +997 Badgettrg talk contribs (→Diagnosis) | ||||
30 April 2024
|
|
18:58 | User:AED 4 changes history +85 [Alara E. Dagsali (4×)] | |||
|
|
18:58 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
|
18:47 (cur | prev) +22 Alara E. Dagsali talk contribs | ||||
|
|
18:28 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
|
18:15 (cur | prev) +23 Alara E. Dagsali talk contribs | ||||
|
|
N 18:58 | Isosulfan Blue 2 changes history +5,962 [Alara E. Dagsali (2×)] | |||
|
|
18:58 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:57 (cur | prev) +5,959 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...") | |||
|
|
N 18:47 | Ibuprofen Lysine 2 changes history +15,666 [Alara E. Dagsali (2×)] | |||
|
|
18:47 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:46 (cur | prev) +15,663 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...") | |||
|
|
N 18:28 | Prussian blue 2 changes history +14,070 [Alara E. Dagsali (2×)] | |||
|
|
18:28 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:27 (cur | prev) +14,067 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...") | |||
|
|
N 18:15 | Botulism Antitoxin 2 changes history +18,011 [Alara E. Dagsali (2×)] | |||
|
|
18:15 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:14 (cur | prev) +18,008 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...") | |||
| m 15:35 | Medication reconciliation diffhist +1 Badgettrg talk contribs | ||||
29 April 2024
| 15:26 | User:AED diffhist +27 Alara E. Dagsali talk contribs | ||||
|
|
N 15:25 | Trastuzumab emtansine 2 changes history +40,575 [Alara E. Dagsali (2×)] | |||
|
|
15:25 (cur | prev) −35 Alara E. Dagsali talk contribs | ||||
| N |
|
15:23 (cur | prev) +40,610 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=AlaraE.Dagsali |genericName=ado-trastuzumab emtansine |indicationType=treatment |indication=the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. the adjuvant treatment...") | |||
28 April 2024
| m 06:33 | Non-degenerate nucleotides per response element diffhist +207 Marshallsumter talk contribs (→Tabulation of counts) | ||||
27 April 2024
|
|
m 20:10 | Non-degenerate nucleotides per response element 2 changes history +1,935 [Marshallsumter (2×)] | |||
| m |
|
20:10 (cur | prev) +301 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:46 (cur | prev) +1,634 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 00:49 | Chronic obstructive pulmonary disease history and symptoms diffhist +2,903 Kosar Doraghi talk contribs | ||||
26 April 2024
|
|
m 20:03 | Non-degenerate nucleotides per response element 2 changes history +2,239 [Marshallsumter (2×)] | |||
| m |
|
20:03 (cur | prev) +608 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:34 (cur | prev) +1,631 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:32 | User creation log User account Jonathan Reyes talk contribs was created by Alberto Castro Molina talk contribs | ||||
| 04:27 | Daprodustat diffhist +1,079 Alen Antony talk contribs | ||||
25 April 2024
| 22:53 | Reni Syndrome diffhist −3 Alara E. Dagsali talk contribs | ||||
|
|
N 22:52 | User:AED 3 changes history +3,204 [Alara E. Dagsali (3×)] | |||
|
|
22:52 (cur | prev) −144 Alara E. Dagsali talk contribs | ||||
|
|
22:51 (cur | prev) +407 Alara E. Dagsali talk contribs | ||||
| N |
|
22:39 (cur | prev) +2,941 Alara E. Dagsali talk contribs (Created page with "==Alara Ece Dagsali== '''Alara Ece Dagsali''' <br>'''Contact:''' email: alaraecedagsai99@gmail.com; +905313614710 ==Medical Education== *School of Medicine (M.D.): Istanbul Medipol University 2021- 2024 Demiroglu Bilim University 2018-2021 ==Pages authored/Co-authored/Collaborated== ===2023=== ====Authored:==== *Reni Syndrome ==Work Experience== *Wikidoc - Associate Editor-In-Chief, 2023 - Current *Yeditepe University Hospitals Cardiac Electrophysiology Lab, Ista...") | |||
| 22:48 | Adagrasib diffhist +3 Alara E. Dagsali talk contribs | ||||
| 22:45 | Norelgestromin diffhist +3 Alara E. Dagsali talk contribs | ||||
|
|
22:45 | Tranexamic 6 changes history +1 [Alara E. Dagsali (6×)] | |||
|
|
22:45 (cur | prev) +11 Alara E. Dagsali talk contribs | ||||
|
|
22:44 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) +2 Alara E. Dagsali talk contribs | ||||
|
|
22:41 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
|
22:40 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
22:39 (cur | prev) −14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
| 22:36 | Alara E. Dagsali diffhist +40 Alara E. Dagsali talk contribs | ||||
|
|
N 21:21 | Daprodustat 6 changes history +6,894 [Alen Antony (6×)] | |||
|
|
21:21 (cur | prev) +952 Alen Antony talk contribs | ||||
|
|
20:53 (cur | prev) +1,266 Alen Antony talk contribs | ||||
|
|
19:07 (cur | prev) +2,809 Alen Antony talk contribs | ||||
|
|
17:23 (cur | prev) +563 Alen Antony talk contribs | ||||
|
|
16:47 (cur | prev) +147 Alen Antony talk contribs | ||||
| N |
|
15:23 (cur | prev) +1,157 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=daprodustat |aOrAn=a |drugClass=reversible inhibitor of HIF-PH1, PH2 and PH3. |indicationType=treatment |indication=anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. |hasBlackBoxWarning=Yes |adverseReactions=Hypertension, Abdominal pain, Dizzines, Hypersensitivity, and thrombotic vascular events like Myocardial infarction, stroke, pulmonary embolism,...") | |||
|
|
m 17:37 | Non-degenerate nucleotides per response element 2 changes history +3,020 [Marshallsumter (2×)] | |||
| m |
|
17:37 (cur | prev) +705 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:56 (cur | prev) +2,315 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:03 | Chronic hypertension medical therapy diffhist +715 Badgettrg talk contribs (→Impact of Blood Pressure self-monitoring in Hypertension Control) | ||||
|
|
01:50 | Bexagliflozin 4 changes history +3,949 [Alen Antony (4×)] | |||
|
|
01:50 (cur | prev) +1,145 Alen Antony talk contribs | ||||
|
|
00:57 (cur | prev) +669 Alen Antony talk contribs | ||||
|
|
00:50 (cur | prev) +1,349 Alen Antony talk contribs | ||||
|
|
00:17 (cur | prev) +786 Alen Antony talk contribs | ||||
24 April 2024
|
|
N 23:35 | Bexagliflozin 4 changes history +1,938 [Alen Antony (4×)] | |||
|
|
23:35 (cur | prev) +245 Alen Antony talk contribs | ||||
|
|
23:11 (cur | prev) +1,453 Alen Antony talk contribs | ||||
|
|
22:55 (cur | prev) +164 Alen Antony talk contribs | ||||
| N |
|
21:06 (cur | prev) +76 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=bexagliflozin }}") | |||
| 23:17 | Endocarditis overview diffhist +5,051 Kosar Doraghi talk contribs | ||||
|
|
23:04 | (Upload log) [Kosar Doraghi (2×)] | |||
|
|
23:04 Kosar Doraghi talk contribs uploaded File:IMG 1177.jpeg | ||||
|
|
22:59 Kosar Doraghi talk contribs uploaded File:IMG 1176.jpeg | ||||
|
|
m 23:02 | Non-degenerate nucleotides per response element 4 changes history +4,215 [Marshallsumter (4×)] | |||
| m |
|
23:02 (cur | prev) +2,787 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
19:16 (cur | prev) +570 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
06:39 (cur | prev) +506 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
04:26 (cur | prev) +352 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
N 21:26 | Tranexamic 7 changes history +23,022 [Alara E. Dagsali (7×)] | |||
|
|
21:26 (cur | prev) +14 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
21:26 (cur | prev) −11 Alara E. Dagsali talk contribs | ||||
|
|
21:25 (cur | prev) −2 Alara E. Dagsali talk contribs Tag: Manual revert | ||||
|
|
21:23 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
|
|
21:23 (cur | prev) +3 Alara E. Dagsali talk contribs Tag: Visual edit: Switched | ||||
|
|
21:22 (cur | prev) −1 Alara E. Dagsali talk contribs | ||||
| N |
|
21:14 (cur | prev) +23,020 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Tranexamic |aOrAn=a |drugClass=hemophilia drug |indicationType=prevention |indication=Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. |adverseReactions=Thromboembolic Risk Seizures Hypersensitivity Reactions Visual Disturbances Dizzines...") | |||
|
|
N 21:25 | Template:AlaraE.Dagsali 2 changes history +74 [Alara E. Dagsali (2×)] | |||
|
|
21:25 (cur | prev) −14 Alara E. Dagsali talk contribs | ||||
| N |
|
21:21 (cur | prev) +88 Alara E. Dagsali talk contribs (Created page with " Alara Ece Dagsali, M.D.[mailto:alaraecedagsali99@gmail.com]") | |||
| 18:12 | Hospital readmissions diffhist +640 Badgettrg talk contribs (→Adults) | ||||
|
|
07:55 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 2 changes history +2,023 [Hafiza Amna Qadeer (2×)] | |||
|
|
07:55 (cur | prev) +965 Hafiza Amna Qadeer talk contribs | ||||
|
|
07:52 (cur | prev) +1,058 Hafiza Amna Qadeer talk contribs (added clinical features) Tag: Visual edit | ||||
23 April 2024
|
|
m 20:09 | Non-degenerate nucleotides per response element 2 changes history +1,082 [Marshallsumter (2×)] | |||
| m |
|
20:09 (cur | prev) +108 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
09:01 (cur | prev) +974 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 15:32 | User creation log User account Malaika Hassan talk contribs was created by Alberto Castro Molina talk contribs | ||||
22 April 2024
|
|
m 20:10 | Non-degenerate nucleotides per response element 2 changes history +204 [Marshallsumter (2×)] | |||
| m |
|
20:10 (cur | prev) +153 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
09:11 (cur | prev) +51 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
18:44 | (Upload log) [Alara E. Dagsali (2×)] | |||
|
|
18:44 Alara E. Dagsali talk contribs uploaded File:D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg | ||||
|
|
18:43 Alara E. Dagsali talk contribs uploaded File:Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG | ||||
21 April 2024
|
|
m 22:07 | Non-degenerate nucleotides per response element 4 changes history +3,558 [Marshallsumter (4×)] | |||
| m |
|
22:07 (cur | prev) +11 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
21:47 (cur | prev) +817 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:02 (cur | prev) +405 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
03:31 (cur | prev) +2,325 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
N 04:03 | BRENZAVVY- bexagliflozin 2 changes history +12,281 [Kosar Doraghi (2×)] | |||
|
|
04:03 (cur | prev) +198 Kosar Doraghi talk contribs | ||||
| N |
|
03:47 (cur | prev) +12,083 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D. [mailto:k.doraghi@yahoo.com] |genericName=BRENZAVVY- bexagliflozin |aOrAn=a |drugClass=sodium-glucose co-transporter 2 (SGLT2) inhibitor |indicationType=treatment |indication=glycemic control in adults with type 2 diabetes mellitus |hasBlackBoxWarning=Yes |adverseReactions=female genital mycotic infections, urinary tract infection and increased urination |blackBoxWarningTitle=Warnings |blackBoxWarningBody=*Not re...") | |||
|
|
03:48 | (Upload log) [Kosar Doraghi (4×)] | |||
|
|
03:48 Kosar Doraghi talk contribs uploaded File:IMG 1052.jpeg | ||||
|
|
03:43 Kosar Doraghi talk contribs uploaded File:IMG 1050.jpeg | ||||
|
|
03:40 Kosar Doraghi talk contribs uploaded File:IMG 1051.jpeg | ||||
|
|
03:34 Kosar Doraghi talk contribs uploaded File:IMG 1049.jpeg | ||||
20 April 2024
|
|
23:33 | User:Imam Ali Shah 6 changes history 0 [Imam Ali Shah (6×)] | |||
|
|
23:33 (cur | prev) −184 Imam Ali Shah talk contribs (→adada) Tag: Manual revert | ||||
|
|
23:33 (cur | prev) +184 Imam Ali Shah talk contribs Tag: Visual edit: Switched | ||||
|
|
23:31 (cur | prev) −964 Imam Ali Shah talk contribs (→jahdijahjdh) Tag: Manual revert | ||||
|
|
23:31 (cur | prev) +964 Imam Ali Shah talk contribs (→Communication Languages) | ||||
|
|
23:26 (cur | prev) −5,843 Imam Ali Shah talk contribs Tags: Manual revert Visual edit: Switched | ||||
|
|
23:24 (cur | prev) +5,843 Imam Ali Shah talk contribs | ||||
|
|
m 20:03 | Non-degenerate nucleotides per response element 2 changes history +255 [Marshallsumter (2×)] | |||
| m |
|
20:03 (cur | prev) +51 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:14 (cur | prev) +204 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m 17:23 | H box gene transcriptions diffhist 0 Marshallsumter talk contribs (→H box (Mitchell) consensus sequences) | ||||
|
|
N 16:19 | Template:IAS 3 changes history +75 [Imam Ali Shah (3×)] | |||
|
|
16:19 (cur | prev) −33 Imam Ali Shah talk contribs | ||||
|
|
16:11 (cur | prev) +19 Imam Ali Shah talk contribs | ||||
| N |
|
16:05 (cur | prev) +89 Imam Ali Shah talk contribs (Created page with "Associate Editor-In-Chief: Imam Ali Shah, MBBS; Chandka Medical College, Larkana Pakistan") | |||
| 03:21 | User:Edzelco diffhist +31 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| 03:20 | Cipaglucosidase alfa-atga diffhist +38,269 Edzelco talk contribs | ||||
19 April 2024
|
|
m 21:06 | Non-degenerate nucleotides per response element 4 changes history −3,707 [Marshallsumter (4×)] | |||
| m |
|
21:06 (cur | prev) +757 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
19:50 (cur | prev) −5,407 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:50 (cur | prev) +779 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
01:58 (cur | prev) +164 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
20:03 | Template:KDRG 2 changes history +60 [Kosar Doraghi (2×)] | |||
|
|
20:03 (cur | prev) +129 Kosar Doraghi talk contribs | ||||
|
|
19:53 (cur | prev) −69 Kosar Doraghi talk contribs | ||||
| N 16:30 | Sparsentan diffhist +8,644 Kosar Doraghi talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi[mailto:k.doraghi@yahoo.com] |genericName=sparsentan |aOrAn=an |drugClass=endothelin and angiotensin II receptor antagonist |indicationType=treatment |indication=proteinuria(reduce) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g |hasBlackBoxWarning=Yes |adverseReactions=Hepatotoxicity, Embryo-Fetal Tox...") | ||||
|
|
16:24 | (Upload log) [Kosar Doraghi (4×)] | |||
|
|
16:24 Kosar Doraghi talk contribs uploaded File:IMG 1046.jpeg | ||||
|
|
16:14 Kosar Doraghi talk contribs uploaded File:IMG 1045.jpeg | ||||
|
|
16:11 Kosar Doraghi talk contribs uploaded File:IMG 1047.jpeg | ||||
|
|
16:05 Kosar Doraghi talk contribs uploaded File:IMG 1044.jpeg | ||||
| 16:17 | Somatic symptom disorder diffhist +485 Badgettrg talk contribs (→Treatment) | ||||
18 April 2024
|
|
m 22:49 | Non-degenerate nucleotides per response element 4 changes history +2,760 [Marshallsumter (4×)] | |||
| m |
|
22:49 (cur | prev) +564 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
20:37 (cur | prev) +1,206 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:39 (cur | prev) +727 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
04:35 (cur | prev) +263 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
m 18:29 | Xenobiotic response element gene transcriptions 2 changes history +93 [Marshallsumter (2×)] | |||
| m |
|
18:29 (cur | prev) +29 Marshallsumter talk contribs (→QRDRE analysis and results) | |||
| m |
|
18:27 (cur | prev) +64 Marshallsumter talk contribs (→QRDRE analysis and results) | |||
| 12:48 | User:Edzelco diffhist +96 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
12:45 | Momelotinib 2 changes history +34,070 [Edzelco (2×)] | |||
|
|
12:45 (cur | prev) −220 Edzelco talk contribs | ||||
|
|
12:44 (cur | prev) +34,290 Edzelco talk contribs | ||||
| 12:12 | Motixafortide diffhist +26,053 Edzelco talk contribs | ||||
| 11:49 | Pozelimab-bbfg diffhist +2,390 Edzelco talk contribs | ||||
| 11:42 | Palovarotene diffhist +39,181 Edzelco talk contribs | ||||
| 11:16 | Elranatamab-bcmm diffhist +32,847 Edzelco talk contribs | ||||
| 06:18 | Endocarditis overview diffhist +2,588 Kosar Doraghi talk contribs | ||||
17 April 2024
|
|
N 20:47 | SCAPULOPERONEAL SPINAL MUSCULAR ATROPHY 3 changes history +364 [Hafiza Amna Qadeer (3×)] | |||
|
|
20:47 (cur | prev) −13 Hafiza Amna Qadeer talk contribs (minor edit) Tag: Visual edit | ||||
|
|
20:46 (cur | prev) +377 Hafiza Amna Qadeer talk contribs (new page minor edit) Tag: Visual edit | ||||
| N |
|
19:33 (cur | prev) 0 Hafiza Amna Qadeer talk contribs (Created blank page) | |||
|
|
m 18:11 | Non-degenerate nucleotides per response element 2 changes history +601 [Marshallsumter (2×)] | |||
| m |
|
18:11 (cur | prev) +438 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
06:52 (cur | prev) +163 Marshallsumter talk contribs (→Tabulation of counts) | |||
| N 08:08 | Elranatamab-bcmm diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:08 | Palovarotene diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:08 | Pozelimab-bbfg diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:07 | Motixafortide diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:07 | Momelotinib diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:06 | Cipaglucosidase alfa-atga diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:05 | Etrasimod diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:05 | Zilucoplan diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Bimekizumab diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Vamorolone diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:04 | Mirikizumab-mrkz diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
| N 08:03 | Toripalimab-tpzi diffhist +53 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} }}") | ||||
|
|
08:02 | User:Edzelco 5 changes history +99 [Edzelco (5×)] | |||
|
|
08:02 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:53 (cur | prev) +26 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:44 (cur | prev) 0 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:44 (cur | prev) +36 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
07:43 (cur | prev) +19 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 08:02 | Fruquintinib diffhist +25,648 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=fruquintinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy |fdaLIADAdult=Recommended Dosage The recommended dose of F...") | ||||
|
|
N 07:53 | Taurolidine, heparin 2 changes history +9,993 [Edzelco (2×)] | |||
|
|
07:53 (cur | prev) 0 Edzelco talk contribs | ||||
| N |
|
07:52 (cur | prev) +9,993 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{Edzelco}} |genericName=taurolidine, heparin |aOrAn=a |drugClass=combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant |indicationType=prevention |indication=atheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients...") | |||
| N 07:43 | Repotrectinib diffhist +32,783 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=repotrectinib |aOrAn=a |drugClass=kinase inhibitor |indicationType=treatment |indication=adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) |contraindications=None |warnings=5.1 Central Nervous System Adverse Reactions AUGTYRO can cause central nervous system adverse reactions. Among the 351 patients who received AUGTYRO in Study TRIDENT-1, a broad spectru...") | ||||
|
|
N 07:34 | Efbemalenograstim alfa-vuxw 3 changes history +20,126 [Edzelco (3×)] | |||
|
|
07:34 (cur | prev) 0 Edzelco talk contribs | ||||
|
|
07:33 (cur | prev) +51 Edzelco talk contribs | ||||
| N |
|
07:32 (cur | prev) +20,075 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |genericName=efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=prevention |indication=incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |fdaLIADAdult=Recommended Dose: 20 mg administered subcutaneously once per chemotherapy cycle....") | |||
| 04:20 | Endocarditis overview diffhist +9,001 Kosar Doraghi talk contribs | ||||
16 April 2024
|
|
m 17:29 | Non-degenerate nucleotides per response element 2 changes history +606 [Marshallsumter (2×)] | |||
| m |
|
17:29 (cur | prev) +201 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:14 (cur | prev) +405 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
15:06 | Trismus 3 changes history +1,038 [M. Arsalan Bashir (3×)] | |||
|
|
15:06 (cur | prev) 0 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
15:00 (cur | prev) +223 M. Arsalan Bashir talk contribs | ||||
|
|
13:30 (cur | prev) +815 M. Arsalan Bashir talk contribs (→Treatment) | ||||
|
|
05:50 | User:Edzelco 2 changes history +33 [Edzelco (2×)] | |||
|
|
05:50 (cur | prev) +18 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
|
|
05:28 (cur | prev) +15 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 05:50 | Capivasertib diffhist +34,175 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=Capivasertib |aOrAn=a |drugClass=kinase inhibitor in combination with fulvestrant |indicationType=treatment |indication=adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based...") | ||||
| N 05:27 | Iptacopan diffhist +33,311 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=iptacopan |aOrAn=a |drugClass=complement factor B inhibitor |indicationType=treatment |indication=paroxysmal nocturnal hemoglobinuria |blackBoxWarningTitle=WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA |blackBoxWarningBody=<span style="clear;"> FABHALTA increases the risk of serious and life-threatening infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria me...") | ||||
| 01:37 | Birch triterpenes diffhist +1,569 Rafael Garcia talk contribs | ||||
15 April 2024
|
|
m 20:06 | Non-degenerate nucleotides per response element 2 changes history +1,954 [Marshallsumter (2×)] | |||
| m |
|
20:06 (cur | prev) +875 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:42 (cur | prev) +1,079 Marshallsumter talk contribs | |||
| 18:43 | Hand contracture diffhist −11 Dj talk contribs | ||||
| 07:25 | User:Edzelco diffhist +16 Edzelco talk contribs (→Pages Authored/Co-authored/Collaborated) | ||||
| N 07:24 | Vutrisiran diffhist +17,228 Edzelco talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{EdzelCo}} |genericName=vutrisiran |aOrAn=a |drugClass=transthyretin-directed small interfering RNA |indicationType=treatment |indication=polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. |adverseReactions=pain in extremity, arthralgia, dyspnea, and decreased vitamin A levels. |fdaLIADAdult=Recommended Dosage The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous inj...") | ||||
14 April 2024
|
|
m 20:07 | Non-degenerate nucleotides per response element 3 changes history +2,087 [Marshallsumter (3×)] | |||
| m |
|
20:07 (cur | prev) +100 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
17:58 (cur | prev) +512 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:09 (cur | prev) +1,475 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 17:41 | Somatic symptom disorder diffhist +992 Badgettrg talk contribs (→Overview) | ||||
| 14:19 | Systematic review diffhist +554 Badgettrg talk contribs (→Meta-narrative reviews) | ||||
13 April 2024
|
|
m 17:15 | Non-degenerate nucleotides per response element 2 changes history +435 [Marshallsumter (2×)] | |||
| m |
|
17:15 (cur | prev) +324 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:00 (cur | prev) +111 Marshallsumter talk contribs (→Tabulation of counts) | |||
12 April 2024
|
|
m 20:10 | Non-degenerate nucleotides per response element 2 changes history +1,137 [Marshallsumter (2×)] | |||
| m |
|
20:10 (cur | prev) +538 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:45 (cur | prev) +599 Marshallsumter talk contribs (→Tabulation of counts) | |||
| 05:15 | User talk:Matt Pijoan diffhist +1,485 Marshallsumter talk contribs (→MALT1: new section) | ||||
11 April 2024
| 20:06 | User creation log User account Bilal Farhat Ali talk contribs was created by Alberto Castro Molina talk contribs | ||||
|
|
m 07:14 | Non-degenerate nucleotides per response element 2 changes history +2,007 [Marshallsumter (2×)] | |||
| m |
|
07:14 (cur | prev) +4 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:06 (cur | prev) +2,003 Marshallsumter talk contribs (→Tabulation of counts) | |||
10 April 2024
| 19:31 | Endocarditis overview diffhist +177 Kosar Doraghi talk contribs | ||||
| 19:20 | Upload log Kosar Doraghi talk contribs uploaded File:IMG 1037.jpeg | ||||
|
|
m 19:12 | Non-degenerate nucleotides per response element 3 changes history +2,127 [Marshallsumter (3×)] | |||
| m |
|
19:12 (cur | prev) +895 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:53 (cur | prev) +1,176 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
00:43 (cur | prev) +56 Marshallsumter talk contribs (→Tabulation of counts) | |||
9 April 2024
|
|
m 17:21 | Non-degenerate nucleotides per response element 3 changes history +1,700 [Marshallsumter (3×)] | |||
| m |
|
17:21 (cur | prev) +173 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
06:47 (cur | prev) +771 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
05:00 (cur | prev) +756 Marshallsumter talk contribs (→Tabulation of counts) | |||
8 April 2024
|
|
m 17:35 | Non-degenerate nucleotides per response element 3 changes history +1,219 [Marshallsumter (3×)] | |||
| m |
|
17:35 (cur | prev) +407 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:02 (cur | prev) +286 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:15 (cur | prev) +526 Marshallsumter talk contribs (→Tabulation of counts) | |||
7 April 2024
|
|
m 23:06 | Non-degenerate nucleotides per response element 3 changes history +584 [Marshallsumter (3×)] | |||
| m |
|
23:06 (cur | prev) +34 Marshallsumter talk contribs | |||
| m |
|
20:33 (cur | prev) +117 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:50 (cur | prev) +433 Marshallsumter talk contribs (→Tabulation of counts) | |||